Nervonik Secures $52.5M Series B for Nerve Stimulation Tech

Nervonik, a Los Angeles-based clinical-stage medical device company, closed an oversubscribed $52.5 million Series B financing round on April 27, 2026. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital. This funding supports the continued development and commercialization of Nervonik's proprietary peripheral nerve stimulation system, which incorporates advanced sensing capabilities for next-generation neuromodulation therapies .

The capital infusion positions Nervonik to accelerate clinical progress and market entry for its PNS platform, aimed at treating conditions through targeted nerve stimulation. As a player in the growing neuromodulation field, Nervonik's technology advances beyond traditional implants by integrating smart sensing features, enhancing precision in peripheral nerve therapies. This Series B milestone reflects strong investor confidence in the company's potential to address unmet needs in pain management and neurological treatments within the healthcare sector .

Nervonik's focus on peripheral nerve stimulation differentiates it in the medtech landscape, where demand for minimally invasive neuromodulation solutions is rising. The oversubscribed nature of the round underscores the technology's promise, enabling expanded R&D and regulatory efforts to bring the system to patients. This funding bolsters Nervonik's trajectory amid increasing investments in innovative medical devices for chronic conditions .